AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05854290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
Study NCT05854290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifiable lifestyle factors
Description: The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
Study NCT05854290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care Psychoeducation
Description: Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
Study NCT06508554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptonomy
Description: 5. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
Study NCT05785299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: clinical introduction of cow's milk
Study NCT05785299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: clinical introduction of placebo
Study NCT05785299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Home introduction
Description: home introduction of cow's milk
Study NCT04982029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 100 MG/ML [Epidiolex]
Description: 600mg
Study NCT04982029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05144152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: M3
Description: A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
Study NCT05144152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: faecal immunochemical test
Study NCT05484401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200Mg Oral Cap
Description: 2 x 200mg Liquid Capsules once in 12 hours
Study NCT05484401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200Mg Oral Tablet
Description: 2 x 200mg Tablets once in 12 hours
Study NCT05484401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liquid Capsule
Description: 2 x Liquid Capsules once in 12 hours
Study NCT05484401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Liquid Capsule
Description: 2 x Liquid Capsules once in 12 hours
Study NCT05484401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: 2 x Tablets once in 12 hours
Study NCT05484401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: 2 x Tablets once in 12 hours
Study NCT06359964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal Biopsy without antibiotics prophylaxis
Description: Transperineal Biopsy without antibiotics prophylaxis
Study NCT06359964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal Biopsy with antibiotics prophylaxis
Description: Transperineal Biopsy with antibiotics prophylaxis
Study NCT06418932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UrgoK2 / UrgoK2 Lite
Description: Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
Study NCT06418932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controll
Description: Administration of parenteral diuretics only
Study NCT04920162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biospecimen into patients who had skin diseases
Description: Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
Study NCT06056063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halcyon 4.0
Description: This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
Study NCT05446376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-citrate PET/CT
Description: PET/CT Imaging with 68Ga-citrate PET/CT injection
Study NCT06156631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH-ExMAMI
Description: The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
Study NCT05354206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology assessment - corticospinal tract
Description: Kinematics and cortical spinal motor excitability
Study NCT05354206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology assessment - reticulospinal tract
Description: Kinematics and reticular spinal motor excitability
Study NCT05354206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with some stimulation
Description: Motor task combined with real or sham stimulation
Study NCT05854745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBB Virtual Training
Description: HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
Study NCT05854745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBB In-person Training
Description: HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
Study NCT05595161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Bodies
Description: The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
Study NCT06000007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app
Description: 2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
Study NCT06000007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
Study NCT06415669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: 100 mg/m2, day 1, day 8, every 21 days for a cycle.
Study NCT06415669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg or 1200mg, the first day, every 21 days as a cycle.
Study NCT06415669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate
Description: 250mg once a day for 5 consecutive days and discontinue for 2 days
Study NCT06462469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
Study NCT06214780 — intervention group
Intervention type: DEVICE
Intervention: advanced hybrid closed-loop
Description: An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions.
Study NCT06095362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
Study NCT04846075 — intervention group
Intervention type: BEHAVIORAL
Intervention: Ramadan fasting, praying, and welfare for poor
Description: Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
Study NCT04457323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
Study NCT04457323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
Study NCT05448690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two different approaches
Description: Please refer to Groups
Study NCT05448690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-combined approach
Description: Either transnasal, transcranial or a staged approach
Study NCT06018740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Balance Gummy
Description: Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
Study NCT05433558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Rehabilitation
Description: Neuropsychological Rehabilitation
Study NCT05430516 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04891549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band fixation
Description: Fracture fixation of the patella fracture with tension band.
Study NCT04891549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plate fixation
Description: Fracture fixation of the patella fracture with a plate.
Study NCT04955938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
Study NCT04955938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
Study NCT04955938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
Study NCT06536868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
Study NCT04684797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual T-maze task
Description: Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
Study NCT05010109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Functional Test
Description: Participate in 6 MWT
Study NCT05010109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT05010109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT
Study NCT06536868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).
Study NCT06536868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
Study NCT05010109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiogram
Study NCT05010109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Cardiac Stress Test
Description: Undergo stress test
Study NCT05010109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05010109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study NCT06536868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: IMRT 30-45Gy/10-15f
Study NCT06446973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35 patients with meniscus tear
Description: Have meniscus pathologies in one or both knees confirmed by MRI.
Study NCT06325774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: 54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study NCT06580821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucogingigval surgery
Description: Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
Study NCT06580821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mucogingigval surgery
Description: Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
Study NCT04742738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
Study NCT04742738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution) - Stage 1
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study NCT04742738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
Study NCT04742738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
Study NCT04742738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
Study NCT04742738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution)- Stage 2
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study NCT05044234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral
Study NCT05044234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cedirogant
Description: Capsule, Oral
Study NCT05044234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral
Study NCT06058897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
Study NCT06058897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye-tracking
Description: Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
Study NCT06058897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive exams
Description: Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
Study NCT06014255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
Study NCT06014255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Radical prostatectomy within 4-8 weeks of randomization.
Study NCT05078645 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Maya
Description: The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy